May 4, 2024
Neoadjuvant relatlimab and nivolumab in resectable melanoma – Nature

Neoadjuvant relatlimab and nivolumab in resectable melanoma – Nature

Nature, Published online: 26 October 2022; doi:10.1038/s41586-022-05368-8

Patients with resectable clinical stage III or oligometastatic stage IV melanoma were given neoadjuvant relatlimab and nivolumab combination immunotherapy, which induced a high pathologic complete response rate, indicating the efficacy and safety of this regimen.

Source link